Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Palau Pharma (worldwide rights to lbaconazole development product)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Worldwide rights to Palau Pharma's Albaconazole development product. The drug is an oral antifungal agent for the treatment of vulvo-vaginal candidiasis, onychomycosis and other antifungal applications.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Commercial Services
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • Pol. Ind. Riera de Caldes Avinguda Camí Reial 51-57
  • Palau-solità i Plegamans
  • 08184 Barcelona
  • Spain

Palau Pharma (worldwide rights to lbaconazole development product) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Palau Pharma (worldwide rights to lbaconazole development product)‘s full profile, request access.

Request full access to PitchBook

Palau Pharma (worldwide rights to lbaconazole development product) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Palau Pharma (worldwide rights to lbaconazole development product)‘s full profile, request access.

Request full access to PitchBook